Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks
Sponsor: Longboard Pharmaceuticals
Listed as NCT05626634, this PHASE2 trial focuses on Developmental and Epileptic Encephalopathy and Dravet Syndrome and remains completed. Sponsored by Longboard Pharmaceuticals, it has been updated 15 times since 2022, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
15 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 10 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
First recorded
Nov 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Longboard Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .